Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Large-Cell, Anaplastic 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 5Brentuximab Vedotin 5Vincristine 4Rituximab 4Peripheral Blood Stem Cell Transplantation 4Ifosfamide 4Etoposide 4Doxorubicin 4Carboplatin 4romidepsin 3fludarabine phosphate 3brigatinib 3Prednisone 3Lenalidomide 3Everolimus 310-propargyl-10-deazaaminopterin 3pembrolizumab 2indolepropanol phosphate 2Whole-Body Irradiation 2Vorinostat 2Mycophenolic Acid 2Microarray Analysis 2Immunohistochemistry 2Gene Expression Profiling 2Cytarabine 2Cyclosporine 2Clofarabine 2Bendamustine Hydrochloride 2veliparib 1repotrectinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Lymphoma, Large-Cell, Anaplastic × ceritinib × Clear all
NCT02729961 2019-10-10

Ceritinib With Brentuximab Vedotin in Treating Patients With ALK-Positive Anaplastic Large Cell Lymphoma

University of Washington

Phase 1/2 Withdrawn
Lymphoid

Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡